{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=High+Grade+Osteosarcoma&page=2", "query": { "condition": "High Grade Osteosarcoma", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=High+Grade+Osteosarcoma&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-06-25T19:01:28.062Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00091182", "title": "Oxaliplatin in Treating Young Patients With Recurrent Solid Tumors That Have Not Responded to Previous Treatment", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Childhood Central Nervous System Germ Cell Tumor", "Childhood Extragonadal Germ Cell Tumor", "Childhood Hepatoblastoma", "Childhood Hepatocellular Carcinoma", "Childhood High-grade Cerebral Astrocytoma", "Childhood Low-grade Cerebral Astrocytoma", "Childhood Malignant Ovarian Germ Cell Tumor", "Childhood Malignant Testicular Germ Cell Tumor", "Childhood Teratoma", "Recurrent Adrenocortical Carcinoma", "Recurrent Childhood Brain Stem Glioma", "Recurrent Childhood Cerebellar Astrocytoma", "Recurrent Childhood Cerebral Astrocytoma", "Recurrent Childhood Ependymoma", "Recurrent Childhood Liver Cancer", "Recurrent Childhood Malignant Germ Cell Tumor", "Recurrent Childhood Rhabdomyosarcoma", "Recurrent Childhood Soft Tissue Sarcoma", "Recurrent Childhood Visual Pathway and Hypothalamic Glioma", "Recurrent Colon Cancer", "Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor", "Recurrent Nasopharyngeal Cancer", "Recurrent Neuroblastoma", "Recurrent Osteosarcoma", "Recurrent Rectal Cancer", "Recurrent Renal Cell Cancer" ], "interventions": [ { "name": "oxaliplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "21 Years", "sex": "ALL", "summary": "Up to 21 Years" }, "enrollment_count": 180, "start_date": "2004-10", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-06-05", "last_synced_at": "2026-06-25T19:01:28.062Z", "location_count": 1, "location_summary": "Arcadia, California", "locations": [ { "city": "Arcadia", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00091182" }, { "nct_id": "NCT00160719", "title": "HLA Sensitization Following Major Cortical Allograft Bone Procedures", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Bone Cancer" ], "interventions": [ { "name": "retrieve blood samples", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE" ], "sponsor": "University of Florida", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "12 Years to 80 Years" }, "enrollment_count": 10, "start_date": "1999-09", "completion_date": "2010-03", "has_results": false, "last_update_posted_date": "2012-10-30", "last_synced_at": "2026-06-25T19:01:28.062Z", "location_count": 1, "location_summary": "Gainesville, Florida", "locations": [ { "city": "Gainesville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00160719" }, { "nct_id": "NCT02180867", "title": "Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Alveolar Soft Part Sarcoma", "Angiomatoid Fibrous Histiocytoma", "Atypical Fibroxanthoma", "Clear Cell Sarcoma of Soft Tissue", "Epithelioid Malignant Peripheral Nerve Sheath Tumor", "Epithelioid Sarcoma", "Extraskeletal Myxoid Chondrosarcoma", "Extraskeletal Osteosarcoma", "Fibrohistiocytic Neoplasm", "Fibrosarcoma", "Inflammatory Myofibroblastic Tumor", "Intimal Sarcoma", "Leiomyosarcoma", "Liposarcoma", "Liver Embryonal Sarcoma", "Low Grade Fibromyxoid Sarcoma", "Low Grade Myofibroblastic Sarcoma", "Malignant Peripheral Nerve Sheath Tumor", "Malignant Skin Granular Cell Tumor", "Malignant Triton Tumor", "Mesenchymal Chondrosarcoma", "Myxofibrosarcoma", "Myxoid Chondrosarcoma", "Myxoinflammatory Fibroblastic Sarcoma", "Nerve Sheath Neoplasm", "PEComa", "Pericytic Neoplasm", "Plexiform Fibrohistiocytic Tumor", "Sclerosing Epithelioid Fibrosarcoma", "Skin Glomus Tumor", "Stage IB Soft Tissue Sarcoma AJCC v7", "Stage IIB Soft Tissue Sarcoma AJCC v7", "Stage III Soft Tissue Sarcoma AJCC v7", "Stage IV Soft Tissue Sarcoma AJCC v7", "Synovial Sarcoma", "Undifferentiated High Grade Pleomorphic Sarcoma of Bone" ], "interventions": [ { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Doxorubicin Hydrochloride", "type": "DRUG" }, { "name": "Ifosfamide", "type": "DRUG" }, { "name": "Pazopanib", "type": "DRUG" }, { "name": "Pazopanib Hydrochloride", "type": "DRUG" }, { "name": "Radiation Therapy", "type": "RADIATION" }, { "name": "Therapeutic Conventional Surgery", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "RADIATION", "PROCEDURE" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": null, "sex": "ALL", "summary": "2 Years and older" }, "enrollment_count": 140, "start_date": "2014-08-12", "completion_date": "2026-03-31", "has_results": true, "last_update_posted_date": "2026-06-17", "last_synced_at": "2026-06-25T19:01:28.062Z", "location_count": 365, "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 240 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" } ], "official_url": "https://clinicaltrials.gov/study/NCT02180867" }, { "nct_id": "NCT04730349", "title": "A Study of Bempegaldesleukin (BEMPEG: NKTR-214) in Combination With Nivolumab in Children, Adolescents and Young Adults With Recurrent or Treatment-resistant Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Ependymoma", "Ewing Sarcoma", "High-grade Glioma", "Leukemia and Lymphoma", "Medulloblastoma", "Miscellaneous Brain Tumors", "Miscellaneous Solid Tumors", "Neuroblastoma", "Relapsed, Refractory Malignant Neoplasms", "Rhabdomyosarcoma" ], "interventions": [ { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "NKTR-214", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "30 Years", "sex": "ALL", "summary": "Up to 30 Years" }, "enrollment_count": 15, "start_date": "2021-06-03", "completion_date": "2022-06-22", "has_results": true, "last_update_posted_date": "2023-03-24", "last_synced_at": "2026-06-25T19:01:28.062Z", "location_count": 2, "location_summary": "Little Rock, Arkansas • St Louis, Missouri", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT04730349" }, { "nct_id": "NCT00445965", "title": "Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Brain and Central Nervous System Tumors", "Intraocular Melanoma", "Lung Cancer", "Melanoma (Skin)", "Metastatic Cancer", "Neuroblastoma", "Ovarian Cancer", "Retinoblastoma", "Sarcoma", "Small Intestine Cancer" ], "interventions": [ { "name": "DNA analysis", "type": "GENETIC" }, { "name": "immunologic technique", "type": "OTHER" }, { "name": "pharmacological study", "type": "OTHER" }, { "name": "iodine I 131 monoclonal antibody 3F8", "type": "RADIATION" }, { "name": "131I-3F8", "type": "RADIATION" } ], "intervention_types": [ "GENETIC", "OTHER", "RADIATION" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 78, "start_date": "2006-01", "completion_date": "2023-02-01", "has_results": true, "last_update_posted_date": "2024-04-04", "last_synced_at": "2026-06-25T19:01:28.062Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00445965" }, { "nct_id": "NCT04238819", "title": "A Study of Abemaciclib (LY2835219) in Combination With Other Anti-Cancer Treatments in Children and Young Adult Participants With Solid Tumors, Including Neuroblastoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Relapsed Solid Tumor", "Refractory Solid Tumor" ], "interventions": [ { "name": "Abemaciclib", "type": "DRUG" }, { "name": "Irinotecan", "type": "DRUG" }, { "name": "Temozolomide", "type": "DRUG" }, { "name": "Dinutuximab", "type": "DRUG" }, { "name": "GM-CSF", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "21 Years", "sex": "ALL", "summary": "Up to 21 Years" }, "enrollment_count": 47, "start_date": "2020-11-09", "completion_date": "2025-08-19", "has_results": true, "last_update_posted_date": "2026-03-02", "last_synced_at": "2026-06-25T19:01:28.062Z", "location_count": 12, "location_summary": "Phoenix, Arizona • Los Angeles, California • Oakland, California + 9 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Oakland", "state": "California" }, { "city": "Roseville", "state": "California" }, { "city": "Santa Clara", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04238819" }, { "nct_id": "NCT04616248", "title": "In Situ Immunomodulation With CDX-301, Radiation Therapy, CDX-1140 and Poly-ICLC in Patients w/ Unresectable and Metastatic Solid Tumors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Anatomic Stage IV Breast Cancer AJCC v8", "Metastatic Breast Carcinoma", "Prognostic Stage IV Breast Cancer AJCC v8", "Unresectable Breast Carcinoma", "Metastatic Melanoma", "Unresectable Melanoma", "Cutaneous Squamous Cell Carcinoma", "Merkel Cell Carcinoma", "Soft Tissue Sarcoma", "Bone Sarcoma", "Sarcoma,Soft Tissue", "Sarcoma of Bone", "Basal Cell Carcinoma" ], "interventions": [ { "name": "Anti-CD40 Agonist Monoclonal Antibody CDX-1140", "type": "BIOLOGICAL" }, { "name": "Poly ICLC", "type": "DRUG" }, { "name": "Radiation Therapy", "type": "RADIATION" }, { "name": "Recombinant Flt3 Ligand", "type": "BIOLOGICAL" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Tocilizumab", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "RADIATION" ], "sponsor": "University of Southern California", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 14, "start_date": "2023-01-09", "completion_date": "2028-01-09", "has_results": false, "last_update_posted_date": "2026-06-18", "last_synced_at": "2026-06-25T19:01:28.062Z", "location_count": 2, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04616248" }, { "nct_id": "NCT00840047", "title": "Methionine PET/CT Studies In Patients With Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Brain Tumors and/or Solid Tumors Including", "Brain Stem Glioma", "High Grade CNS Tumors", "Ependymoma", "Medulloblastoma", "Craniopharyngioma", "Low Grade CNS Tumors", "Hodgkin Lymphoma", "Non Hodgkin Lymphoma", "Ewing Sarcoma", "Osteosarcoma", "Rhabdomyosarcoma", "Neuroblastoma", "Other" ], "interventions": [ { "name": "Methionine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "St. Jude Children's Research Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 503, "start_date": "2009-07-20", "completion_date": "2027-07-27", "has_results": false, "last_update_posted_date": "2026-06-17", "last_synced_at": "2026-06-25T19:01:28.062Z", "location_count": 1, "location_summary": "Memphis, Tennessee", "locations": [ { "city": "Memphis", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT00840047" }, { "nct_id": "NCT00880542", "title": "Sorafenib and Ifosfamide in Treating Patients With High-Grade Soft Tissue Sarcoma or Bone Sarcoma That Can Be Removed by Surgery", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Sarcoma" ], "interventions": [ { "name": "sorafenib", "type": "DRUG" }, { "name": "Ifosfamide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Jonsson Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 7, "start_date": "2008-08", "completion_date": null, "has_results": true, "last_update_posted_date": "2020-08-10", "last_synced_at": "2026-06-25T19:01:28.062Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00880542" }, { "nct_id": "NCT00743509", "title": "A Phase II Study of Oral Cyclophosphamide and Sirolimus (OCR) in Advanced Sarcoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Osteosarcoma" ], "interventions": [ { "name": "Cyclophosphamide and Sirolimus", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Michigan Rogel Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": null, "sex": "ALL", "summary": "16 Years and older" }, "enrollment_count": 49, "start_date": "2008-08", "completion_date": "2012-09", "has_results": true, "last_update_posted_date": "2015-09-28", "last_synced_at": "2026-06-25T19:01:28.062Z", "location_count": 1, "location_summary": "Ann Arbor, Michigan", "locations": [ { "city": "Ann Arbor", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT00743509" } ] }